Document Detail

Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis.
MedLine Citation:
PMID:  18662929     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate whether statins are associated with a protective effect on the development of rheumatoid arthritis (RA).
METHODS: A nested case-control study was conducted using data from the General Practice Research Database. A study population consisting of three groups of subjects aged 40-89 years was identified: (1) patients exposed to a statin or other lipid-lowering agent (LLA); (2) patients with a diagnosis of hyperlipidaemia in the absence of lipid-lowering drug treatment and (3) a random sample of 25 000 individuals with no diagnosis of hyperlipidaemia nor a prescription for a LLA. From this population incident cases of RA and up to four controls for each case were identified, matched on age, sex, general practice, number of years of recorded history in the database and index date. The independent effects of hyperlipidaemia and statins on the development of RA were evaluated using conditional logistic regression.
RESULTS: 313 cases of RA and 1252 matched controls were identified. Compared with patients with untreated hyperlipidaemia, or hyperlipidaemia treated with LLA other than statins, the adjusted odds ratio for patients with no hyperlipidaemia was 0.68 (95% CI 0.50 to 0.91). When those with hyperlipidaemia who received statins were compared with those with hyperlipidaemia who did not use statins (ie, untreated hyperlipidaemia patients or those treated with non-statin LLA) the OR was 0.59 (95% CI 0.37 to 0.96).
CONCLUSION: These data provide evidence to support the hypothesis that statins may be protective against the development of RA in patients with hyperlipidaemia.
S S Jick; H Choi; L Li; I B McInnes; N Sattar
Related Documents :
19193199 - Oxidative stress and myeloperoxidase levels in saliva of patients with recurrent aphtho...
23829439 - Monitoring of β-amyloid dynamics after human traumatic brain injury.
12784389 - All-cause mortality and vascular events among patients with rheumatoid arthritis, osteo...
22352839 - Nitric oxide modulation of low-frequency oscillations in cortical vessels in fhm--a nir...
3880279 - Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human di...
10419869 - Polymorphic cag repeats of the androgen receptor gene and rheumatoid arthritis.
21883679 - Airway dimensions and pulmonary function in chronic obstructive pulmonary disease and b...
12350429 - Transcranial magnetic stimulation after pure motor stroke.
3791649 - Parenteral bromocriptine in the treatment of hormonally active pituitary tumours.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-07-28
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  68     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-16     Completed Date:  2009-04-27     Revised Date:  2011-12-01    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  546-51     Citation Subset:  IM    
Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts 02421, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Rheumatoid / complications,  prevention & control*
Case-Control Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipidemias / complications,  drug therapy*
Hypolipidemic Agents / therapeutic use*
Logistic Models
Middle Aged
Odds Ratio
Grant Support
S0673//Arthritis Research UK
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Hypolipidemic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is there an acceleration of the CpG transition rate during the mammalian radiation?
Next Document:  Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes.